Kevin Klos
Neurological Surgery · Tulsa, OKNPI 1912923012
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,965 of the $20,697 with a category attached, or 82.0%. Amneal Pharmaceuticals LLC accounts for 89.7% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $18,586, more than ten times the $123 reported in 2019.
Across 54 payments — averaging $383.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$19K
- Acorda Therapeutics, Inc$1K
- Abbott$404
- Boston Scientific$196
- Medtronic$68
- Sunovion Pharmaceuticals Inc.$42
- plus $63 from 3 others
Across 232 payments — averaging $17,095 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.5M
- Roche TCRC, Inc.$1M
- AbbVie$419K
- Amneal Pharmaceuticals LLC$409K
- UCB SA$376K
- Sage Therapeutics, LLC$161K
- plus $114K from 5 others
What the payments were for
- Consulting fees$1,3657%
- Speaking & faculty fees$16,96582%
- Travel & lodging$1781%
- Food & beverage$8734%
- Education$1,3166%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 17 | $18,559 |
| Acorda Therapeutics, Inc | 1 | $1,365 |
| Abbott | 17 | $404 |
| Boston Scientific | 8 | $196 |
| Medtronic(2 entities) | 3 | $68 |
| Sunovion Pharmaceuticals Inc. | 4 | $42 |
| MDD US Operations, LLC | 2 | $26 |
| Avion Pharmaceuticals | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,697 in reported general payments places this provider in the 75th percentile of 80 neurological surgery providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 210 | $192,582 |
| NeuproRotigotine | 52 | $66,559 |
| XadagoSafinamide Mesylate | 13 | $15,677 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 337 | $15,475 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 42 | $12,435 |
| CrexontCarbidopa/Levodopa | 20 | $11,853 |
| AmantadineAmantadine Hcl | 161 | $10,929 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 137 | $9,994 |
| Pramipexole ErPramipexole Di-Hcl | 12 | $8,093 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 87 | $6,577 |
| Entacapone | 20 | $3,906 |
| Midodrine Hcl | 26 | $3,313 |
| RivastigmineRivastigmine Tartrate | 26 | $3,277 |
| Selegiline Hcl | 20 | $1,999 |
| Ropinirole Hcl | 67 | $1,925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary, Crexont | $18,559 | $204,435230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 80 neurological surgery providers in Oklahoma.
Other neurological surgery in Tulsa
- Clinton BairdTulsa$621K
- Michael ThambuswamyTulsa$92K
- Daniel HarwellTulsa$63K
- Mohammad Yashar KalaniTulsa$23K
- Tyler AuschwitzTulsa$17K
- Brian HoodTulsa$13K
- Shihao ZhangTulsa$8K
- Donald SchleicherTulsa$6K
- John MaroukTulsa$4K
- Scott DullTulsa$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.